Acquisition Announced

Novartis acquisition of Myricx Bio

US$1.1bn consideration

Announced 6 Jul 2026

Advisers

Myricx Bio

Target

Novartis

Acquirer

Not disclosed

Target
Myricx Bio
Acquirer
Novartis
Target based in
United Kingdom
Buyer based in
Switzerland
Sector
Biotech
Tags
Biotech, Oncology

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.